Remifentanil-Propofol Sedation as an Ambulatory Anesthesia for Carpal Tunnel Release

Jae-Jun Lee, M.D.,1 Sung Mi Hwang, M.D., Ph.D.,1 Ji Su Jang, M.D.,1 So Young Lim, M.D., Ph.D.,1 Dong-Hwa Heo, M.D., Ph.D.,2 Yong Jun Cho, M.D., Ph.D.2

Departments of Anesthesiology and Pain Medicine,1 Neurosurgery,2 Chuncheon Sacred Heart Hospital, School of Medicine, Hallym University, Chuncheon, Korea

Objective: This prospective study evaluated the use of continuous sedation using propofol and remifentanil when carpal tunnel release (CTR) was performed under local anesthesia.

Methods: We sedated 60 patients undergoing CTR using local anesthesia with remifentanil at loading and continuous doses of 0.5 µg kg⁻¹ and 0.05 µg kg⁻¹ min⁻¹, respectively, and propofol, using a target controlled infusion (TCI) pump set to a target of 2 µg mL⁻¹ (group A), or with the same drug doses except that the continuous remifentanil dose was 0.07 µg kg⁻¹ min⁻¹ (group B) or 0.1 µg kg⁻¹ min⁻¹ (group C).

Results: In group B, the levels of pain when local anesthetics were administered (p = 0.001), intraoperative pain (p < 0.001) and anxiety (p = 0.001) were significantly lower than those of group A. Furthermore, the incidence of adverse events, including desaturation (p < 0.001) and vomiting (p = 0.043), was significantly lower in group B than in group C.

Conclusion: Continuous sedation using an appropriate dose of remifentanil and propofol can be used as safe, efficacious ambulatory anesthesia in cases of CTR under local anesthesia, performed using only 2 mL of local anesthetic, with a high degree of patient satisfaction.

KEY WORDS: Carpal tunnel syndrome • Propofol • Remifentanil.
to receive a remifentanil injection at loading and continuous doses of 0.5 µg kg\(^{-1}\) and 0.05 µg kg\(^{-1}\)/min\(^{-1}\), respectively, with propofol, using a target controlled infusion (TCI) pump set to a target of 2 µg mL\(^{-1}\) (group A), or injection of remifentanil at a loading and continuous dose of 0.5 µg kg\(^{-1}\) and 0.07 µg kg\(^{-1}\)/min\(^{-1}\) with the same propofol dose (group B), or injection of remifentanil at loading and continuous doses of 0.5 µg kg\(^{-1}\) and 0.1 µg kg\(^{-1}\)/min\(^{-1}\) with the same dose of propofol (group C) for sedation.

### Sedation

After arrival in the operating room, noninvasive arterial pressure (NIBP), heart rate (HR), pulse oximetry (SpO\(_2\)), and electrocardiography (ECG) were monitored. All patients were given O\(_2\) at a rate of 5 L min\(^{-1}\) using a face mask. After an initial monitoring of group A, patients received a remifentanil injection at a loading dose of 0.5 µg kg\(^{-1}\) and a continuous dose of 0.05 µg kg\(^{-1}\)/min\(^{-1}\). The sedation level was assessed using the Observer’s Assessment of Alertness/Sedation (OAA/S) scale, modified by reversing the order of the scores (with a composite score of 1 = awake and alert to 5 = unresponsive\(^{10}\)). Five minutes after the remifentanil injection, propofol was infused using a TCI pump set to a target of 2 µg mL\(^{-1}\). After completing administration of the loading and continuous doses of the study drugs, an operator blinded to the experimental groups draped the operation site and injected local anesthetic along the site of the incision using 2 mL, and then performed the CTR. The operation was performed using a tourniquet. In groups B and C, we used the same method of sedation as in group A, except that the continuous doses of remifentanil were 0.07 and 0.1 µg kg\(^{-1}\)/min\(^{-1}\), respectively.

### Operative procedure

We resected the transverse carpal ligament using a mini-open skin incision under tourniquet control. An approximately 2-cm skin incision was made and the transverse carpal ligament was identified after dissecting the subcutaneous soft tissue. Then, the skin was retracted proximally and distally, and the overlying hypertrophied transverse carpal ligament was resected. After resecting the carpal ligament, we confirmed complete resection of the ligament and decompression of the median nerve.

### Outcome measures of sedation

The sedation level was assessed by different investigators during the operation. An investigator graded the patient sedation status using an OAA/S scale score. At 2 h after surgery, the patients were questioned by anesthesiologists in the recovery room. Pain when local anesthetic was applied and during the operation, including tourniquet pain, was assessed using a visual analog scale (VAS) : 0 = no pain to 10 = severe pain. Anxiety was assessed using a VAS : 0 = no anxiety to 10 = most anxiety. Sedation satisfaction was also assessed using a VAS : 0 = extremely dissatisfied to 10 = extremely satisfied. Adverse events, including postoperative headache, nausea, and vomiting, were checked.

### Statistical analyses

We used a nonparametric test for the statistical analysis because of the small sample size. Statistical analyses were performed using SPSS software (ver. 12; SPSS, Chicago, IL, USA), and p values < 0.05 were deemed to indicate statistical significance. Ratio data were analyzed using the Kruskal-Wallis test, and nominal data were analyzed using the Pearson chi-squared test. Mean VAS scores for pain at the local anesthetic injection site, pain during the operation, anxiety, headache, satisfaction, and OAA/S scale scores were compared between groups using the Kruskal-Wallis test. The incidence of anxiety, headache, nausea, vomiting, and hypoxemia, was compared between groups using the Pearson chi-squared test.

### RESULTS

#### Patient demographics

The three groups were similar with respect to age, gender, height, weight, and duration of anesthesia and surgery (Table 1).

#### Pain on administration of local anesthetics and during the operation

In group A, nine patients had injection pain and their mean VAS score was 3.89/10, whereas seven patients had operation pain and their mean VAS score was 3.14/10. As a result, the overall pain score for group A was 1.8/10 at the injection site and 1.1/10 during the operation. By contrast, in group B, three patients felt pain only at the injection site, and their mean pain score was 2/10, whereas the overall group B score was 0.3/10. None of group C patients experienced pain. The mean injection pain scores for group A were significantly higher than those of groups B and C (p = 0.001). Additionally, the mean operation pain scores for group A were significantly higher than those of groups B and C (p < 0.001) (Table 2).

#### Anxiety during the operation

In group A, nine patients felt anxiety, and their mean VAS anxiety score was 2.78/10. As a result, the overall anxiety score for group A was 1.25/10. By contrast, in group B, only one patient felt anxious, and her anxiety score was 3/10,
whereas the overall group B score was 0.15/10. Furthermore, none of group C patients felt anxiety. The incidence of anxiety in group A was significantly higher than that of groups B and C (p = 0.001), and the mean anxiety score for group A was significantly higher than that of groups B and C (p = 0.001) (Table 2).

**Depth of sedation**

The level of sedation, as graded on the OAA/S scale, remained between 2 and 4 in the three groups, except for three patients in group C who sometimes had an OAA/S scale score of 5. A statistically significant difference was noted between group A and groups B and C. The group A OAA/S scale score was significantly lower than that of groups B and C (p = 0.030).

**Respiratory Evaluation**

In group C, desaturation (< 90%) developed in nine patients (45%), and the SpO2 decreased significantly from 15 min after propofol injection. All patients in groups A and B maintained SpO2 levels above 97%. The incidence of hypoxemia in group C was significantly higher than that in groups A and B (p < 0.001) (Table 2).

**Satisfaction with sedation**

The average VAS satisfaction scores for groups A, B, and C were 7.2/10, 8.15/10, and 7.65/10, respectively. Patients in group B tended to have a higher satisfaction score than those in groups A and C, but the difference was not statistically significant (Table 2).

**Adverse events**

The incidence of adverse events was the highest in group C in which seven (35%) patients complained of nausea. Six (30%) of the seven patients had headache, and three (15%) patients of the seven vomited. In group B, three (15%) patients had a headache and two (10%) of the three patients complained of nausea. None of patients in group A experienced any adverse events. The incidence (p = 0.029) and mean score (p = 0.024) for headache in groups B and C were significantly higher than those of group A. The incidence (p = 0.006) and mean score (p = 0.005) for nausea in groups B and C were significantly higher than those of group A. The incidence of vomiting (p = 0.043) in group C was significantly higher than that in groups A and B (Table 2).

**DISCUSSION**

Anesthetic techniques used for CTR include general anesthesia, local anesthetic infiltration, intravenous regional anesthesia, and peripheral nerve block, either proximally at the brachial plexus or more distally at the peripheral nerves. The choice of anesthetic technique for CTR should ensure a bloodless operative field, without anatomical distortion, to enable clear identification of the transverse carpal ligament and median nerve, avoiding injury to the palmar cutaneous branch of the median nerve18).

Local anesthesia for CTR is the simplest, most cost-effective technique, providing rapid onset and prolonged anesthesia with no motor block19). Altissimi and Mancini1) described a technique of infiltrating 4–5 mL of 2% mepivacaine into the carpal tunnel in addition to infiltrating 3–4 mL of the same anesthetic into the subcutaneous tissue. They reported complete analgesia in most patients. However, they stressed the risk of median nerve injury. Furthermore, large volumes of local anesthetic can cause anatomical distortion. In this study, our sedation allowed local anesthetic infiltration along the site of the incision using only 2 mL, which resulted in no anatomical change, subcutaneous swelling, or median nerve injury.

To avoid median nerve injury, Gale5) suggested that local anesthetic be injected only into the subcutaneous tissues. Gibson5) reported slight discomfort on incising the flexor
retinaculum in four of 98 patients and Baguneid et al.2) reported that 13% of patients had slight discomfort during the operation using similar techniques. Pail et al.4) compared the administration of local anesthetic into the carpal tunnel combined with subcutaneous infiltration (the modified Altissimi and Mancini technique) with only subcutaneous infiltration (the modified Gale technique). The mean pain scores on administration of the local anesthetic were 3.2 and 3.3, respectively, using a numerical rating scale (NRS) with the modified Gale and modified Altissimi and Mancini techniques. Of the 20 patients, six experienced intraoperative pain (NRS scores 8, 7, 5, 4, 2, and 2) with the modified Gale technique, whereas no patient experienced pain with the modified Altissimi and Mancini technique. Vossinaakis20) identified three distinct causes of the discomfort associated with the administration of the local anesthetic before surgery.

In our study, pain on administration of the local anesthetic was significantly low, although we infiltrated only 2 mL subcutaneously. The modified Gale technique and the original Gale technique injected 6 mL and 5-8 mL of 2% plain lidocaine, respectively. Furthermore, during the operation, groups B and C had no pain, including tourniquet pain. Tourniquet pain is another important point of anesthetic consideration. Several authors believe that some patients do not tolerate the conventional upper arm tourniquet when awake8,13). In our study, the patients who were sedated before local anesthetic infiltration tolerated both the tourniquet pain and infiltration pain well. Kwon et al.10) reported that endoscopic CTR under local anesthesia with upper arm tourniquet had excellent results compared with conventional surgery. We think that our sedation can be also used in this endoscopic CTR, and the patients may be more comfortable with the infiltration pain and tourniquet pain.

Sedation with sedative and analgesic agents has become popular for painful procedures and surgery under local anesthesia. Our sedation technique with propofol and remifentanil produced less pain and anxiety during the operation, while maintaining the advantages of local anesthesia and allowing outpatient surgery. The sedative propofol has a pharmacokinetic profile that is well-suited for continuous infusion because it has a rapid onset of action, short duration of effect, and minimal postanesthetic side effects36,20). Furthermore, the high clearance and favorable recovery profile of propofol offer advantages over other intravenous sedatives for ambulatory surgery25,22). Remifentanil is a short-acting, selective µ-opioid agonist with a rapid onset of effect and a rapid offset that is independent of the duration of infusion. The termination of its therapeutic effect is primarily dependent on metabolism by circulating plasma esterases, rather than redistribution4,7). Consequently, remifentanil has a pharmacokinetic profile well-suited for rapid recovery, even for more prolonged outpatient procedures requiring moderate-to-high levels of intraoperative analgesia. However, some studies have reported that patients receiving a continuous remifentanil infusion experience nausea, vomiting, headache, or pruritus3,9,12).

In our study, all of the groups showed overall satisfaction with the sedation. Although there was not a statistically significant difference, the satisfaction scores of the three groups showed some tendencies that were due to the different continuous remifentanil doses. In group A, nine patients felt injection pain and seven felt operative pain. In group B, three patients felt pain only at the injection site, and their mean pain score was 2/10, whereas the overall group B score was 0.3/10. In group C, which received the highest continuous remifentanil dose, no patient felt pain. In terms of complications, however, the group-C patients had many adverse events; the most common was nausea (35%), followed by headache (30%) and vomiting (15%). Three patients in group B developed a headache and no group-A patient experienced such complications. Considering all of our results, we conclude that the appropriate continuous dose of remifentanil was 0.07 µg kg⁻¹ min⁻¹ with a loading dose of 0.5 µg kg⁻¹ in combination with propofol given with a TCI pump set to a target of 2 µg mL⁻¹.

**CONCLUSION**

Continuous sedation using an appropriate dose of remifentanil and propofol can be used to provide safe, efficacious ambulatory anesthesia for CTR under local anesthesia, with a high degree of patient satisfaction. Furthermore, with this sedation, local anesthesia can be performed using subcutaneous infiltration of only 2 mL, which do not cause anatomical distortion or median nerve injury.

**References**

1. Altissimi M, Mancinic GB : Surgical release of the median nerve under local anesthesia for carpal tunnel syndrome. J Hand Surg Br 13 : 395-396, 1988
2. Baguneid MS, Sochart DH, Dunlop D, Kenny NW : Carpal tunnel decompression under local anaesthetic and tourniquet control. J Hand Surg Br 22 : 322-324, 1997
3. Chernik DA, Gillings D, Laine H, Hendler J, Silver JM, Davidson AB, et al. : Validity and reliability of the Observer’s Assessment of Alertness/Sedation Scale : study with intravenous midazolam. J Clin Psychopharmacol 10 : 244-251, 1990
4. Egan TD, Lemmens HJ, Fiset P, Hermann DJ, Muir KT, Stanski DR, et al. : The pharmacokinetics of the new short-acting opioid remifentanil (G187084B) in healthy adult male volunteers. Anesthesiology 79 : 881-892, 1993
5. Gale DW : Surgical decompression of the carpal tunnel using infiltrative anaesthesia : description of technique. J R Coll Surg Edinburgh 36 : 341, 1991
6. Gibson M : Outpatient carpal tunnel decompression without tourni-
Sedation for Carpal Tunnel Release | JJ Lee, et al.

7. Glass PS, Hardman D, Kamiyama Y, Quill TJ, Marton G, Donn KH, et al.: Preliminary pharmacokinetics and pharmacodynamics of an ultra-short-acting opioid: remifentanil (G187084B). *Anesth Analg* 77: 1031-1040, 1993

8. Glynn A, Strunck S, Reidy D, Hynes DE: Carpal tunnel release using local anaesthetic and a forearm tourniquet. *Ir Med J* 98: 144-145, 2005

9. Gold MI, Watkins WD, Sung YF, Yarmush J, Chung F, Uy NT, et al.: Remifentanil versus remifentanil/midazolam for ambulatory surgery during monitored anesthesia care. *Anesthesiology* 87: 51-57, 1997

10. Kwon YJ, Kim TS, Lim YJ, Rhee BA, Leem W, Kim GK: The clinical analysis of patients with carpal tunnel syndrome underwent surgery: comparison between conventional and endoscopic surgery. *J Korean Neurosurg Soc* 29: 372-378, 2000

11. Litchman HM, Silver CM, Simon SO, Motamed M, Deutch SO: Carpal tunnel release, efficacy as an ambulatory outpatient procedure under local anaesthesia. *Orthop Rev* 13: 167-171, 1984

12. Mingus ML, Monk TG, Gold MI, Jenkins W, Roland C: Remifentanil versus propofol as adjuncts to regional anesthesia. Remifentanil 3010 Study Group. *J Clin Anesth* 10: 46-53, 1998

13. Ng ES, Ting JR, Foo SL, Akram SA, Fadzliana AA, Alywiah JS, et al.: The comparison of discomfort level between upper arm and forearm tourniquet. *Med J Malaysia* 61 Suppl B: 23-26, 2006

14. Patil S, Ramakrishnan M, Stothard J: Local anesthesia for carpal tunnel decompression: a comparison of two techniques. *J Hand Surg Br* 31: 683-686, 2006

15. Phalen GS: The carpal-tunnel syndrome. Seventeen years’ experience in diagnosis and treatment of six hundred fifty-four hands. *J Bone Joint Surg Am* 48: 211-228, 1966

16. Sebel PS, Lowdon JD: Propofol: a new intravenous anesthetic. *Anesthesiology* 71: 260-277, 1989

17. Shafer SL: Advances in propofol pharmacokinetics and pharmacodynamics. *J Clin Anesth* 5: 145-215, 1993

18. Sinha A, Chan V, Anastakis DJ: Anesthesia for carpal tunnel release. *Can J Anesth* 50: 323-327, 2003

19. Tomaino MM, Ulizio D, Vogt MT: Carpal tunnel release under intravenous regional or local infiltration anesthesia. *J Hand Surg Br* 26: 67-68, 2001

20. Vossinakis IC: Re: reduction in pain associated with open carpal tunnel decompression. *J Hand Surg Br* 26: 503-504, 2001

21. White PF: Clinical pharmacology of intravenous induction drugs. *Int Anesthesiol Clin* 26: 98-104, 1988

22. White PF: Propofol: pharmacokinetics and pharmacodynamics. *Semin Anesth* 1: 4-20, 1988